A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy

Status Active, not recruiting

Clinical Trial Summary

This study will have two parts. The main aims are to: - check the side effects from mezagitamab. - check for long-term side effects from mezagitamab. Before starting the study, participants will be asked to provide a 24-hour urine sample. A few weeks later, if enrolled they will begin receiving a subcutaneous injection (under the skin) of mezagitamab once a week for 8 weeks then once every 2 weeks for 16 weeks. When treatment has ended, there will be a 24-week follow-up period. Participants who receive benefit from the treatment may continue in the second part of the study where they will be monitored for up to 96 weeks and possibly retreated for another 24 weeks.

Clinical Trial Description

The drug being tested in this study is called mezagitamab. Mezagitamab is being tested for the first time in this patient population and might help to treat people who have Primary Immunoglobulin (IgA) Nephropathy. This study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of mezagitamab in combination with stable background therapy. The study will enroll approximately 16 participants. The study will consist of 2 key components: a main study and a long-term extension (LTE) study, which includes an observation period and a retreatment period. The observation period of the LTE study is a non-interventional study segment and the retreatment period of the LTE study consists of a redosing period in which participants will be administered mezagitamab at the same dose level as in the main study. Only participants who have a positive outcome during the main study will enter LTE study. Participants will be enrolled to the following cohort: • Mezagitamab This multi-center trial will be conducted in the United States, Europe, and Asia Pacific. The overall time to participate in this study is approximately 154 weeks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05174221
Study type	Interventional
Source	Takeda
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	November 9, 2022
Completion date	March 23, 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02369354` - Transplant Social Worker Support for Live Kidney Donation in African Americans	N/A
Not yet recruiting	`NCT02225782` - Trial to Compare 1.0 Versus 2.0 mg Alteplase (tPA) Dosing in Restoring Hemodialysis Catheter Function	Phase 4
Completed	`NCT00499187` - Fanconi Syndrome Due to ARVs in HIV-Infected Persons	Phase 4
Withdrawn	`NCT00585429` - Evaluation of Kidney Disease in Liver Transplant Recipients	N/A
Completed	`NCT00379899` - ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis	Phase 4
Completed	`NCT00183248` - Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients	Phase 1/Phase 2
Completed	`NCT00001835` - Oxaliplatin in Cancer Patients With Impaired Kidney Function	Phase 1
Completed	`NCT01331941` - A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function	Phase 1
Terminated	`NCT00436748` - Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease	Phase 3
Completed	`NCT01467466` - Prevention of Serious Adverse Events Following Angiography	Phase 3
Completed	`NCT01235936` - Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia	Phase 2
Completed	`NCT01947829` - Interdialytic Kt/V Variability Measurement With Adimea (IVP STUDY)	N/A
Completed	`NCT01974999` - A Retrospective Multicenter Study to Determine 5-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-01 Study
Recruiting	`NCT01240564` - The Nephrotic Syndrome Study Network (NEPTUNE)	N/A
Active, not recruiting	`NCT01228903` - Uric Acid and the Endothelium is CKD	N/A
Completed	`NCT00734357` - Comparative Investigation of Intravenously Administered Omnipaque and Isovue: Effects on Serum Creatinine Concentration in Outpatients	N/A
Completed	`NCT00781417` - Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease	N/A
Completed	`NCT00093977` - Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney Disease	Phase 3
Completed	`NCT00096915` - Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis	Phase 3
Completed	`NCT00185159` - Olmesartan Medoxomil in Diabetes Mellitus	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms